Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

29452 ARTÍCULOS , VIENDO DEL 2371 AL 2385

Anti-amyloid β Antibody Therapies for Alzheimer's Disease: Association between the Target of Amyloid β Aggregates and the Clinical Efficacy of Anti-amyloid β Antibody

Noguchi-Shinohara M, Ono K.

Intern Med. 2026 Jan 1;65(1):67-70. doi: 10.2169/internalmedicine.4604-24. Epub 2024 Oct 11.

Gut Microbiome in Alzheimer's Disease: from Mice to Humans

Liang C, Pereira R, Zhang Y, Rojas OL.

Curr Neuropharmacol. 2024;22(14):2314-2329. doi: 10.2174/1570159X22666240308090741.

β-Amyloids and Immune Responses Associated with Alzheimer's Disease

Kolobova E, Petrushanko I, Mitkevich V, Makarov AA, Grigorova IL.

Cells. 2024 Sep 28;13(19):1624. doi: 10.3390/cells13191624.

Exploring the Benzazoles Derivatives as Pharmacophores for AChE, BACE1, and as Anti-Aβ Aggregation to Find Multitarget Compounds against Alzheimer's Disease

Rosales Hernández MC, Olvera-Valdez M, Velazquez Toledano J, Mendieta Wejebe JE, Fragoso Morales LG, Cruz A.

Molecules. 2024 Oct 9;29(19):4780. doi: 10.3390/molecules29194780.

Intrathecal Immunoselective Nanopheresis for Alzheimer's Disease: What and How? Why and When?

Menendez-Gonzalez M.

Int J Mol Sci. 2024 Oct 2;25(19):10632. doi: 10.3390/ijms251910632.

Potential Mechanisms of Tunneling Nanotube Formation and Their Role in Pathology Spread in Alzheimer's Disease and Other Proteinopathies

Kotarba S, Kozłowska M, Scios M, Saramowicz K, Barczuk J, Granek Z, Siwecka N, Wiese W, Golberg M, Galita G, Sychowski G, Majsterek I, Rozpędek-Kamińska W.

Int J Mol Sci. 2024 Oct 8;25(19):10797. doi: 10.3390/ijms251910797.

Beta-Amyloid Related Neurodegenerative and Neurovascular Diseases: Potential Implications for Transfusion Medicine

Muir RT, Callum JL, Yu AYX, Kapral MK, Swartz RH, Black SE, MacIntosh BJ, Fergusson DA, Kleinman S, Demchuk AD, Stys PK, Smith EE, Hill MD.

Transfus Med Rev. 2024 Oct;38(4):150858. doi: 10.1016/j.tmrv.2024.150858. Epub 2024 Sep 18.

Decreased Brain pH Correlated With Progression of Alzheimer Disease Neuropathology: A Systematic Review and Meta-Analyses of Postmortem Studies

Hagihara H, Miyakawa T.

Int J Neuropsychopharmacol. 2024 Oct 1;27(10):pyae047. doi: 10.1093/ijnp/pyae047.

Brain Stimulation in Alzheimer's Disease Trials

Benussi A, Borroni B.

J Alzheimers Dis. 2024;101(s1):S545-S565. doi: 10.3233/JAD-230535.

Immunotherapy in Alzheimer's Disease: Current Status and Future Directions

Vashisth K, Sharma S, Ghosh S, Babu MA, Ghosh S, Iqbal D, Kamal M, Almutary AG, Jha SK, Ojha S, Bhaskar R, Jha NK, Sinha JK.

J Alzheimers Dis. 2024;101(s1):S23-S39. doi: 10.3233/JAD-230603.

Melatonin in Alzheimer's Disease: Literature Review and Therapeutic Trials

Steinbach MJ, Denburg NL.

J Alzheimers Dis. 2024;101(s1):S193-S204. doi: 10.3233/JAD-230760.

Advances and Challenges in Gene Therapy for Alzheimer's Disease

Morroni F, Caccamo A.

J Alzheimers Dis. 2024;101(s1):S417-S431. doi: 10.3233/JAD-230783.

CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer's Disease Treatment: A Systematic Review of Available Clinical Data

Thitilertdecha P, Brimson JM.

J Alzheimers Dis. 2024;101(s1):S115-S128. doi: 10.3233/JAD-230994.

CMS121, a Novel Drug Candidate for the Treatment of Alzheimer's Disease and Age-Related Dementia

Currais A, Raschke W, Maher P.

J Alzheimers Dis. 2024;101(s1):S179-S192. doi: 10.3233/JAD-231062.

Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer's Disease

Feldman HH, Messer K, Qiu Y, Sabbagh M, Galasko D, Turner RS, Lopez O, Smith A, Durant J, Lupo JL, Revta C, Balasubramanian A, Kuehn-Wache K, Wassmann T, Schell-Mader S, Jacobs DM, Salmon DP, Léger G, DeMarco ML, Weber F; ADCS VIVA-MIND Study Group.

J Alzheimers Dis. 2024;101(s1):S79-S93. doi: 10.3233/JAD-231126.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias